Hôpital Marie-Lannelongue

​

Excellence in treatments of pulmonary and cardiovascular diseases from antenatal stage to adulthood. Over 10000 surgical procedures, catheterization procedures, and 80 heart lung transplants per year.

Learn more on hopitalmarielannelongue.fr

​

​

AP-HP

​

The Department of Respiratory and Intensive Care Medicine of Bicêtre University Hospital is the French Reference Centre of Pulmonary Hypertension. This centre leads the French Network of Pulmonary Hypertension and the National Registry of patients with pulmonary hypertension. In partnership with the INSERM unit UMR_S999, it is highly implicated in the development of novel therapies for pulmonary hypertension and conducts extensive experimental, translational and clinical research in this field. The centre is supported by national and international organisations (ERN-Lung, RespiFil, DHU THORINO, LabEx LERMIT).

​

 

CentraleSupélec

​

CentraleSupélec is an internationally-reputed Higher Education and Research Institution. Its excellence lies in its combination of fundamental and applied sciences for innovation with societal impact. For almost two centuries, CentraleSupélec's top engineers have been practicing their skills and knowledge for the development of corporate institutions and public organizations.
Learn more on centralesupelec.fr

​

 

Commissariat à l'Énergie Atomique

​

Liten, the Laboratory for Innovative Technologies in new Energies and Nanomaterials is a unique combination of technological infrastructure and expertise in R&D to meet the demands of the energy transition. Liten is a major European research institute and a driving force behind the development of the sustainable energy technologies of the future. The institute is spearheading the EU's efforts to limit dependency on fossil fuels and reduce greenhouse gas emissions in three key areas: renewable energy, energy efficiency/storage and development of materials.

Learn more on liten.cea.fr

​
 

CNRS

​

The National Center for Scientific Research, or CNRS, is a public organization under the responsibility of the French Ministry of Education and Research.

Our Missions

Founded in 1939 by governmental decree, the CNRS aims to:

• Evaluate and carry out all research capable of advancing knowledge and bringing social, cultural, and economic benefits for society.

• Contribute to the promotion and application of research results.

• Develop scientific information.

• Support research training.

• Participate in the analysis of the national and international scientific climate and its potential for evolution in order to develop a national policy.

Learn more on www.cnrs.fr

​

​

INSERM U999

​

Pulmonary hypertension describes a group of devastating diseases, comprising idiopathic and associated forms, causing breathlessness, loss of exercise capacity and death due to elevated pulmonary artery pressure and subsequent right heart failure.

Pulmonary arterial hypertension is defined by an elevation of the mean pulmonary artery pressure above 25mmHg at rest and/or 30mmHg during exercise without elevation of the pulmonary capillary wedge pressure. Extensive pulmonary artery remodeling with loss of vessel patency is the underlying pathomechanism.

The main scope of the Research Team "PULMONARY HYPERTENSION PATHOPHYSIOLOGY AND INNOVATIVE THERAPIES" relates to pulmonary hypertension pathophysiology and clinical management. Deciphering of the mechanisms of lung vascular remodelling and identification of novel molecular targets to alleviate and ultimately cure pulmonary hypertension is the main objective of this proposal. On the basis of a nationwide web-based Registry, a biobank, and highly competitive scientists, our group will study a number of molecular pathways causing pulmonary vascular remodelling in human and animal models of pulmonary hypertension identify targets for therapy, foster drug development based on these targets and test novel treatments. Our main goal is to alleviate and cure pulmonary hypertension, a large burden to mankind, and to develop novel therapies.

Learn more on www.u999.universite-paris-saclay.fr

​

​

INSERM U1176

​

Inserm U1176 -Hemostasis, Inflammation and Thrombosis- headed by Dr. Cécile Denis, aims to investigate the fundamental mechanisms driving the cross-talk between the hemostatic system and vascular cells. The ultimate goal is to optimize diagnosis and to develop alternative therapies in hemostasis and thrombosis.

The Unit is composed of two research groups:

• the team of Dr. Cécile DENIS studies the pathophysiological role of coagulation proteins in- and beyond-hemostasis & the pathogenesis of such as

• the team of Prof. Delphine BORGEL studies the in the pathogenesis of vascular diseases, including sepsis and ischemia/reperfusion injuries & the role of blood platelets and calcium in vascular permeability during thrombo-inflammatory diseases.

Learn more on www.umrs1176.universite-paris-saclay.fr

​

 

Université Paris-Saclay (former Université Paris Sud)

​

Paris-Saclay University is a place dedicated to high-level research, focused on understanding the world, backing student success and responding to the needs of society. Its high level of research is evidenced by numerous awards and its position in international rankings. But Paris-Saclay University can also be proud of its leading position among French universities, in terms of integration of students and doctoral students.
Learn more on www.universite-paris-saclay.fr

​

 

Air Liquide

​

Air Liquide Healthcare supplies medical gases, home healthcare services, hygiene products, medical equipment and specialty ingredients.
In 2017, it served over 15,000 hospitals and clinics and more than 1.5 million patients at home throughout the world with the support of its 16,500 employees.
In Home Healthcare, Air Liquide Healthcare, European leader, provides home healthcare services in compliance with medical prescription for patients suffering from chronic diseases such as COPD (Chronic Obstructive Pulmonary Disease), sleep apnea and diabetes.

Learn more on : airliquide.com

​

​

Sensome

​

Sensome developed a breakthrough technology that turns medical devices into connected healthcare devices. Founded in 2014, this spin-off from Ecole polytechnique has developed impedance-based micro-sensors that allow the identification of biological tissues in real time through AI algorithms. Integrated with medical devices, this information can provide physicians with critical insights when making treatment decisions. Sensome is currently developing a smart neurovascular guidewire that can determine the nature of the blood clot blocking a brain artery causing a stroke. Knowing the type of clot causing the stroke could speed-up the process of re-establishing blood flow to the patient's brain. Beyond stroke, Sensome's sensor technology can be deployed in other medical fields, such as interventional cardiology or oncology.

Learn more on Sensome.com

​

​

Xenios

​

XENIOS is dedicated to translating medical need into pioneering therapies and devices together with caregivers and patients.

novalung was formed back in 2003. In 2011, the Aachen-based medos AG was acquired by novalung with the aim of extending medos’ blood pump expertise and blood pump technology for use with lung therapies. Compared to other pumps, the pulsatile blood pump system offered by medos was ideal for this kind of use. This also enabled the company to expand its overall product spectrum to offer both lung and heart support. This makes sense anatomically, since coronary and pulmonary circulation are interrelated. Logically, therefore, products are based on a single technology and use the same platform. The first joint project that resulted is i-cor: syncronized cardiac assist for treatment of cardiogenic shock and circulatory support during cath lab interventions.

In 2013, an initial step was then taken towards a full merger of these two businesses with the formation of a parent holding company, XENIOS.

Learn more on xenios-ag.com